R&D | December 09, 2025
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated
